Statistics for Myriad Genetics (id:7627 MYGN)

Valuation metrics

Market cap

1.43B

Enterprise value

1.48B

Trailing P/E (ttm)

-4.81

Forward P/E

104.53

PEG ratio

104.53

Price/Sales (ttm)

1.73

Price/Book (mrq)

1.95

Enterprise Value/Revenue

1.80

Enterprise Value/EBITDA

-43.65

Overview

Shares outstanding

91.04M

Float

83.48M

Shares short

4.48M

% Held by insiders

0.02%

% Held by institutions

1.06%

Average volume (10 days)

1.60M

Average volume (90 days)

Price summary

52-Week low

14.72

52-Week high

29.30

52-Week change

-17.78%

Beta

1.94

50-Day moving average

23.90

200-Day moving average

23.65

Dividends and splits

Forward annual dividend rate

7.00

Forward annual dividend yield

0.46

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

July 01th, 2009

Last split factor

2:1

Last split date

March 26th, 2009

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-14.08%

Operating margin

-8.34%

Operational effectiveness

Return on assets

-5.35%

Return on equity

-16.40%

Income statement

Revenue (ttm)

9.20

Revenue per share (ttm)

9.20

Quarterly revenue growth (yoy)

Gross profit (ttm)

517.00M

EBITDA

-33,900,000.00

Net income to common (ttm)

-116,000,000.00

Diluted EPS (ttm)

-1.28

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

99.90M

Total cash per share (mrq)

1.10

Total debt (mrq)

143.10M

Total Debt/Equity (mrq)

19.56

Current ratio (mrq)

190.00%

Book value per share (mrq)

8.04

Cash flow

Cash flow statement

-70,000,000.00

Levered free cash flow (LFCF)

-52,900,000.00